Search
News & Events
Investigational vaccine for WA's meningococcal threatPerth researchers have begun a clinical trial of an investigational Meningococcal B vaccine against the most common form of meningococcal disease in W.A.
News & Events
Potential new vaccine for WA's meningococcal threatPerth researchers are trialling a Meningococcal B vaccine that could potentially provide protection
News & Events
Beating the flu bugPerth children are being asked to volunteer for an important national study to test the effectiveness of an influenza vaccine in children.
Research
ImmunisationImmunisation is the most effective way of protecting your child against a range of serious illnesses, including measles, hepatitis B and whooping cough. All vaccines used in Australia undergo stringent testing and ongoing monitoring.
Research
Whooping CoughWhooping cough (pertussis) is a highly contagious respiratory infection which causes a severe cough and can be particularly dangerous to babies under a year old. Vaccination is the best way to reduce the risk of whooping cough.
Research
FeBRILe3: Risk-Stratification and Diagnosis of Serious Bacterial Infections in Febrile Infants Less Than 3 Months OldEvidence-based recommendations exist for early discharge (before 48 h) of young infants with fever without source (FWS) at low risk of serious bacterial infections (SBIs). However, concerns regarding the applicability of international data to local contexts may hinder implementation. We aimed to describe the local epidemiology of FWS and evaluate a newly implemented risk-stratification guideline to support practice change.
Research
Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults who had Previously Received a Meningococcal ACWY VaccineA MenABCWY vaccine containing 4CMenB and MenACWY-CRM vaccine components has been developed to protect against the 5 meningococcal serogroups that cause most invasive disease cases.
Research
Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in AustraliaAustralia's active vaccine safety surveillance system AusVaxSafety monitors a number of vaccines, including Arexvy, by reporting on solicited adverse events following immunisation (AEFI) through an online survey sent to vaccinees 3 days post-vaccination as previously described.3 Here we report on survey responses from adults aged ≥60 years receiving Arexvy at primary healthcare practices or pharmacies, who responded to the survey by day 7 post-vaccination.
Research
Streptococcus pyogenes Surveillance Through Surface Swab Samples to Track the Emergence of Streptococcal Toxic Shock Syndrome in Rural JapanJapan recently experienced a record surge in streptococcal toxic shock syndrome. Our environmental surveillance study reveals that Streptococcus pyogenes persists seasonally, peaking in autumn and winter in rural Japan. The dominant emm1 M1UK sublineage and csrS mutations heighten virulence, highlighting the urgent need for targeted surveillance and interventions.
Pneumococcal – a bacterial infection that can cause pneumonia and meningitis – is responsible for 1000s of hospital admissions in Australia each year, many of them children.